Non-small Cell Lung Cancer
A Study of LY3023414 and Necitumumab in Participants With Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
The results of this study are not yet available.
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have squamous advanced NSCLC (Stage IV)
Participant must have progressed on one prior line of platinum-based chemotherapy
Participant must be able to swallow the study drug (pills) whole
Female participant must not be pregnant or breastfeeding and must agree to have a pregnancy test performed; participants of childbearing potential must agree to use reliable method of birth control during the study and for at least 3 months after stopping study treatment
Participant must not have insulin-dependent diabetes, however participants with type 2 diabetes may be eligible
Participant must not have an active, known fungal, bacterial, and/or known viral infection
Participant must not currently be receiving treatment with warfarin sodium (however, low molecular weight heparin and oral Xa inhibitors are allowed)
Participants must not have received > 1 prior line of chemotherapy in the advanced or metastatic setting (Immunotherapy will not be considered a line of chemotherapy)
Participants must not have received prior treatment with necitumumab